The goal of this clinical trial is to measure the safety and effectiveness of topical diacerein in adults with psoriasis vulgaris. The primary objective of the study is to compare the proportion of participants who achieve a clinically meaningful improvement in disease severity between the topical diacerein group and the dummy treatment (placebo) group.
Official registry: https://clinicaltrials.gov/study/NCT07352306 · Alaa Ashraf Muhammad Helal · enrollment listed as 60
Phase 4: the treatment is already approved. This study asks new questions — longer-term effects, other diseases, or how it compares in everyday care.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
If you join, the listed intervention(s) are Diacerein, or Placebo. The registry lists allocation as randomized. The goal of this clinical trial is to measure the safety and effectiveness of topical diacerein in adults with psoriasis vulgaris.
They plan to enroll about 60 people at Cairo. Taking part typically means taking a study drug (or dummy pill) plus check-ins.
The Efficacy of Topical Diacerein Cream in Patients With Psoriasis Vulgaris
Interventions: Diacerein, Placebo
Primary outcome (registry wording): Proportion of Participants Achieving PASI 75
Alaa A Helal, BSc in Pharmacy
alaa.ashraf.muhammad@std.pharma.cu.edu.eg
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
Treatment of moderate to severe Psoriasis (Pso) and Psoriasis-Arthritis (PsA) is largely confined to systemic therapy in Germany. Systemic therapy includes conventional systemic therapy (e.g.
NCT01848028 · Official ClinicalTrials.gov record · Universitätsklinikum Hamburg-Eppendorf
Glucocorticoids remain to be among the most important and most frequently used anti-inflammatory and immunosuppressive or immune-modulatory acting drugs to treat rheumatic (and other) diseases. Unfortunately, glucocorticoids also exert undesired effects, especially if higher dosages have to be given over longer periods of time.
NCT02719314 · Official ClinicalTrials.gov record · Prof Dr Frank Buttgereit
The purpose of this pediatric study is to measure the drug levels, how well it works and safety of Deucravacitinib in children and adolescent participants aged 4 to \<18 years with moderate to severe plaque psoriasis. This study includes two cohorts; Cohort 1 (age 12 to \<18 years) and Cohort 2 (age 4 to \<12 years), with two parts; for each cohort.
NCT04772079 · Official ClinicalTrials.gov record · Bristol-Myers Squibb
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
Phase 4. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary